Brentuximab vedotin Antibody

SKU: orb1980736

Description

Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) designed to target CD30, delivering the cytotoxic agent monomethyl auristatin E to disrupt microtubules in lymphoma cells. It is widely used in preclinical research for studying Hodgkin lymphoma and systemic anaplastic large cell lymphoma, supporting both in vitro cytotoxicity assays and in vivo xenograft model experiments.

Images & Validation

−

Key Properties

−

CAS Number	914088-09-8
MW	145.58 kDa
Purity	95.00%
Target	Antibody-Drug Conjugates (ADCs)

Bioactivity

−

In Vivo

METHODS: Brentuximab vedotin (0.1 mg/kg, once a week, intravenously), chidamide (15 mg/kg, once a day, orally), or BV combined with chidamide were used to treat severe combined immunodeficient mice bearing tumor xenografts of HH cells mixed with BD Matrigel to study tumor growth in vivo. RESULTS: The combination of brentuximab vedotin and chidamide effectively inhibited tumor growth.

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

SGN-35, Antibody-Drug Conjugates, AntibodyDrug Conjugates (ADCs), AntibodyDrugConjugates(ADCs), AntibodyDrugConjugates, ADCs, ADC linker

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

Antibody-Drug Conjugates (ADCs)

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols